6903 related articles for article (PubMed ID: 2874196)
1. A phase I study of intravenous azimexon therapy in human cancer.
Patt YZ; Hersh EM; Reuben J; Claghorn L; Mavligit G
J Biol Response Mod; 1986 Aug; 5(4):313-8. PubMed ID: 2874196
[TBL] [Abstract][Full Text] [Related]
2. Effect of azimexon therapy on host defense parameters and disease-associated symptoms in the acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC).
Patt YZ; Mansell PW; Reuben JM; Claghorn L; Li S; Gehan E; Hersh EM
AIDS Res; 1986; 2(3):191-209. PubMed ID: 3755909
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
Tan CT; Hancock CH; Mondora A; Hoffman NW
Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
[TBL] [Abstract][Full Text] [Related]
4. Modulation in vitro of immune parameters in homosexual males with the preclinical complex of symptoms related to acquired immune deficiency syndrome by azimexon.
Patt YZ; Mavligit GM; Reuben J; Mansell PW; Li S; Newell G; Talpaz M; Hersh EM
J Biol Response Mod; 1986 Jun; 5(3):263-9. PubMed ID: 3088215
[TBL] [Abstract][Full Text] [Related]
5. [Biological effects of leakadin].
Garin AM; Lichinitser MR; Dmitrieva NV; Rubtsov BI; Leneva NV
Vopr Onkol; 1988; 34(2):192-6. PubMed ID: 2964757
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical evaluation of diaziquone in childhood cancer.
Ettinger LJ; Siegel SE; Belasco JB; Evans AE; Ruccione KS; Jamin DC; Rohrbaugh TM; Higgins GR
Cancer Treat Rep; 1985 Mar; 69(3):323-7. PubMed ID: 3856480
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
Kolitz JE; Wong GY; Welte K; Merluzzi VJ; Engert A; Bialas T; Polivka A; Bradley EC; Konrad M; Gnecco C
J Biol Response Mod; 1988 Oct; 7(5):457-72. PubMed ID: 3263471
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of aziridinylbenzoquinone (NSC 182986).
Bedikian AY; Bodey GP; Burgess MA; Freireich EJ
Cancer Clin Trials; 1981; 4(4):459-63. PubMed ID: 7318128
[TBL] [Abstract][Full Text] [Related]
9. Immunorestoration of anergic cancer patients by azimexon.
Goutner A; Nasrat F; Bonardelle D; Rameau G
Recent Results Cancer Res; 1980; 75():47-52. PubMed ID: 7232839
[TBL] [Abstract][Full Text] [Related]
10. A pilot clinical trial of the toxicity and immunorestorative effects of T cell reconstituting factor (SR 270258) in immunosuppressed cancer patients.
Murray JL; Reuben JM; Smith TL; Gehan EA; Koretz SM; Hersh EM
J Biol Response Mod; 1987 Feb; 6(1):56-68. PubMed ID: 2951501
[TBL] [Abstract][Full Text] [Related]
11. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
[TBL] [Abstract][Full Text] [Related]
12. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of diaziquone in patients with colon cancer.
Neidhart JA; Erlichman C; Robert F; Velez-Garcia E; Bender JF; Grillo-López J
Cancer Treat Rep; 1985 Feb; 69(2):215-7. PubMed ID: 3882229
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of diaziquone.
Frytak S; Eagan RT; Ames MM; Creagan ET; Nichols WC
Cancer Treat Rep; 1984; 68(7-8):975-8. PubMed ID: 6744349
[TBL] [Abstract][Full Text] [Related]
15. Clinical and clinical pharmacologic studies of aziridinylbenzoquinone.
Griffin JP; Newman RA; McCormack JJ; Krakoff IH
Cancer Treat Rep; 1982 Jun; 66(6):1321-5. PubMed ID: 7083235
[TBL] [Abstract][Full Text] [Related]
16. The effect of BM 12.531 (azimexon) on natural killer cell activity in myeloma patients.
Peter HH; Dziuba-Traber H; Boerner D
Eur J Cancer Clin Oncol; 1984 Mar; 20(3):353-9. PubMed ID: 6368246
[TBL] [Abstract][Full Text] [Related]
17. Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials.
Ernstoff MS; Fusi S; Kirkwood JM
J Biol Response Mod; 1983; 2(6):540-7. PubMed ID: 6607324
[TBL] [Abstract][Full Text] [Related]
18. NTP Toxicology and Carcinogenesis Studies of p-Nitrobenzoic Acid (CAS No. 62-23-7) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Dec; 442():1-306. PubMed ID: 12595921
[TBL] [Abstract][Full Text] [Related]
19. Reduction of the immunosuppressive action of chemotherapeutics in patients with mammary carcinoma by Azimexon.
Kreienberg R; Boerner D; Melchert F; Lemmel EM
J Immunopharmacol; 1983; 5(1-2):49-64. PubMed ID: 6606686
[TBL] [Abstract][Full Text] [Related]
20. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
